These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 25776933)

  • 1. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
    Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
    Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
    Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
    Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
    Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
    Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
    Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
    Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
    PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.
    Rebolj M; Cuschieri K; Mathews CS; Pesola F; Denton K; Kitchener H;
    BMJ; 2022 May; 377():e068776. PubMed ID: 35640960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Sequential Rounds of Cervical Cancer Screening on Management of HPV-positive Women: A 15-year Population-based Cohort Study from China.
    Xu XQ; Rezhake R; Hu SY; Chen F; Zhang X; Pan QJ; Zhang WH; Ma JF; Qiao YL; Zhao FH; Cruickshank M
    Cancer Prev Res (Phila); 2021 Mar; 14(3):363-372. PubMed ID: 33303694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.
    Rebolj M; Bonde J; Preisler S; Ejegod D; Rygaard C; Lynge E
    PLoS One; 2016; 11(1):e0147326. PubMed ID: 26789267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triaging women with human papillomavirus infection and normal cytology or low-grade dyskaryosis: evidence from 10-year follow up of the ARTISTIC trial cohort.
    Gilham C; Sargent A; Peto J
    BJOG; 2020 Jan; 127(1):58-68. PubMed ID: 31541495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
    Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
    BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
    Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
    BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA.
    Stoler MH; Baker E; Boyle S; Aslam S; Ridder R; Huh WK; Wright TC
    Int J Cancer; 2020 May; 146(9):2599-2607. PubMed ID: 31490545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the ESTAMPA multicentric screening study.
    Valls J; Baena A; Venegas G; Celis M; González M; Sosa C; Santin JL; Ortega M; Soilán A; Turcios E; Figueroa J; Rodríguez de la Peña M; Figueredo A; Beracochea AV; Pérez N; Martínez-Better J; Lora O; Jiménez JY; Giménez D; Fleider L; Salgado Y; Martínez S; Bellido-Fuentes Y; Flores B; Tatti S; Villagra V; Cruz-Valdez A; Terán C; Sánchez GI; Rodríguez G; Picconi MA; Ferrera A; Mendoza L; Calderón A; Murillo R; Wiesner C; Broutet N; Luciani S; Pérez C; Darragh TM; Jerónimo J; Herrero R; Almonte M;
    Lancet Glob Health; 2023 Mar; 11(3):e350-e360. PubMed ID: 36796982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.